Literature DB >> 29970975

Pain Management in Pediatric Chronic Kidney Disease.

Amanda Reis, Caitlyn Luecke, Thomas Keefe Davis, Aadil Kakajiwala.   

Abstract

Pain is a common problem in children with chronic kidney disease (CKD); however, limited data exist regarding its management. Although most pain is managed pharmacologically, in some instances non-pharmacologic management can aid in safely ameliorating discomfort. Because of the accumulation of toxic metabolites, many common pain medications have adverse effects on kidney function or altered pharmacokinetics in the setting of CKD. Decreased clearance impacts safe dosing of analgesics. The pain management of patients on renal replacement therapy requires an understanding of drug clearance due to the different modalities of dialysis. This educational review highlights pain medications that are safe, albeit often with adjusted dosing, as well as drugs best avoided in the management of pediatric kidney disease. Acetaminophen should be used as a first-line therapy for pain management in children with CKD. Opioids may be added to control moderate to severe pain. Although data are currently lacking, buprenorphine holds promise as a potentially useful drug for the treatment of pain in pediatric patients with CKD. The addition of adjuvant pain medications and non-pharmacologic therapies maybe also be helpful. Despite these options, pain often remains difficult to treat in children with CKD.

Entities:  

Keywords:  analgesia; chronic kidney disease; dialysis; nephrology; pain; pediatrics

Year:  2018        PMID: 29970975      PMCID: PMC6027978          DOI: 10.5863/1551-6776-23.3.192

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  71 in total

1.  Physical therapy for patellofemoral pain: a randomized, double-blinded, placebo-controlled trial.

Authors:  Kay Crossley; Kim Bennell; Sally Green; Sallie Cowan; Jenny McConnell
Journal:  Am J Sports Med       Date:  2002 Nov-Dec       Impact factor: 6.202

Review 2.  Pharmacokinetic evaluation of hydrocodone/acetaminophen for pain management.

Authors:  Aarti Singla; Paul Sloan
Journal:  J Opioid Manag       Date:  2013 Jan-Feb

Review 3.  Gabapentin for chronic neuropathic pain in adults.

Authors:  Philip J Wiffen; Sheena Derry; Rae F Bell; Andrew Sc Rice; Thomas Rudolf Tölle; Tudor Phillips; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-06-09

4.  Case report. Intravenous fentanyl patient-controlled analgesia for perioperative treatment of neuropathic/ischaemic pain in haemodialysis patients: a case series.

Authors:  M Karanikolas; D Aretha; P Kiekkas; G Monantera; I Tsolakis; K S Filos
Journal:  J Clin Pharm Ther       Date:  2010-10       Impact factor: 2.512

5.  PROMIS(®) pediatric self-report scales distinguish subgroups of children within and across six common pediatric chronic health conditions.

Authors:  Darren A DeWalt; Heather E Gross; Debbie S Gipson; David T Selewski; Esi Morgan DeWitt; Carlton D Dampier; Pamela S Hinds; I-Chan Huang; David Thissen; James W Varni
Journal:  Qual Life Res       Date:  2015-02-26       Impact factor: 4.147

Review 6.  New therapy for neuropathic pain.

Authors:  Hirokazu Mizoguchi; Chizuko Watanabe; Akihiko Yonezawa; Shinobu Sakurada
Journal:  Int Rev Neurobiol       Date:  2009       Impact factor: 3.230

Review 7.  Acetaminophen-induced nephrotoxicity: pathophysiology, clinical manifestations, and management.

Authors:  Maryann Mazer; Jeanmarie Perrone
Journal:  J Med Toxicol       Date:  2008-03

8.  Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites.

Authors:  C W Hand; J W Sear; J Uppington; M J Ball; H J McQuay; R A Moore
Journal:  Br J Anaesth       Date:  1990-03       Impact factor: 9.166

Review 9.  Pediatric palliative care: use of opioids for the management of pain.

Authors:  Boris Zernikow; Erik Michel; Finella Craig; Brian J Anderson
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

10.  Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients.

Authors:  Sara N Davison; Patrick R Mayo
Journal:  J Opioid Manag       Date:  2008 Nov-Dec
View more
  2 in total

1.  Kidney Injury Following Ibuprofen and Acetaminophen: A Real-World Analysis of Post-Marketing Surveillance Data.

Authors:  Qi-Hui Shao; Xue-Dong Yin; Hong-Xia Liu; Bin Zhao; Jian-Quan Huang; Zhi-Ling Li
Journal:  Front Pharmacol       Date:  2021-12-22       Impact factor: 5.810

Review 2.  Substance use among adolescents and young adults with chronic kidney disease or kidney failure.

Authors:  Nianzhou Xiao; Hua Chai; Abiodun Omoloja
Journal:  Pediatr Nephrol       Date:  2021-03-09       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.